Matthew Berger, MD
Psychiatry · Moosic, PANPI 1295718237
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,311,001 of the $1,679,905 with a category attached, or 78.0%. It is spread thinly across 36 manufacturers, the largest accounting for just 22.5%. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,486 payments — averaging $675.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$378K
- Otsuka America Pharmaceutical, Inc.$321K
- Neurocrine Biosciences, Inc.$278K
- Axsome Therapeutics, Inc.$159K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$132K
- Johnson & Johnson$112K
- plus $299K from 30 others
Across 264 payments — averaging $2703.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$641K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$16K
- Boehringer Ingelheim$12K
- Corcept Therapeutics$12K
- Avanir Pharmaceuticals, Inc.$10K
- Sage Therapeutics, LLC$9K
- plus $15K from 2 others
What the payments were for
- Consulting fees$173,58010%
- Speaking & faculty fees$1,311,00178%
- Travel & lodging$151,7199%
- Food & beverage$42,7163%
- Education$8890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$314,937
- LYBALVI$273,627
- INGREZZA$272,419
- AUSTEDO$188,008
- Auvelity$155,934
- CAPLYTA$130,036
- UZEDY$121,496
- Fanapt$76,400
- Austedo XR$63,849
- ARISTADA$57,611
- INVEGA SUSTENNA$57,219
- INVEGA TRINZA$56,172
- SPRAVATO$52,072
- VRAYLAR$43,318
- Dayvigo$28,575
- QUVIVIQ$17,383
- LATUDA$9,456
- ZULRESSO$9,413
- Zurzuvae$3,619
- TRINTELLIX$3,231
How this compares
$1,679,905 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 22 | $178,344 |
| AustedoDeutetrabenazine | 17 | $138,896 |
| RexultiBrexpiprazole | 60 | $93,284 |
| FanaptIloperidone | 13 | $78,966 |
| VraylarCariprazine Hcl | 49 | $67,943 |
| AuvelityDextromethorphan Hbr/Bupropion | 51 | $57,593 |
| CaplytaLumateperone Tosylate | 29 | $45,702 |
| Invega SustennaPaliperidone Palmitate | 12 | $37,129 |
| TrintellixVortioxetine Hydrobromide | 33 | $21,383 |
| BelsomraSuvorexant | 31 | $19,644 |
| Lurasidone Hcl | 44 | $11,809 |
| Clomipramine Hcl | 58 | $8,152 |
| EliquisApixaban | 11 | $6,664 |
| Paliperidone ErPaliperidone | 29 | $5,206 |
| Bupropion XlBupropion Hcl | 115 | $4,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $278,304 | $178,34422 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $377,958 | $138,89617 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $320,793 | $93,28460 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $77,515 | $78,96613 claims |
| AbbVieVraylar | $46,516 | $67,94349 claims |
| Axsome Therapeutics, Inc.Auvelity | $159,299 | $57,59351 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $132,463 | $45,70229 claims |
| Johnson & JohnsonInvega Sustenna | $112,029 | $37,12912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $3,810 | $21,38333 claims |
| MerckBelsomra | $187 | $19,64431 claims |
| Almatica Pharma LLCSertraline Hcl | $121 | $1,881160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Moosic
- Satish MallikMoosic$20K
- Rebecca RomaPittsburgh$3.3M
- Robert NelsonWyomissing$2.2M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
- Jane JesseKingston$617K
- Michael ThasePhiladelphia$396K
- Michael KwiatBeaver$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.